How mixed background of ImmuPharma CEO helps to compete with the big pharmaceutical companies

Dimitri F. Dimitriou, MSC, Chief executive officer ImmuPharma has mostly a science background, mixed with some R&D, marketing and sales. He received the Bachelor's degree in the King's College of London and the Master's degree at Imperial Medical School. Dimitri started his career at Novartis in the Marketing dept, then spent some years in Procter & Gamble, then six years in GlaxoSmithKline where he left as a Senior Director for World Wide Business Director. And he was one of the founders in ImmuPharma over 20 years ago.

His expectations about the future of ImmuPharma are concentrated near the US market as the biggest market in the world. He expects a big explosion in the market capitalisation in the next couple of years.

How unique is ImmuPharma in the biotech world? ImmuPharma is focusing on the outsourcing model and they work closely with the french National Institute for Research on the discovery side and then they focus on drugs development. Keeping the company virtual helps to keep the costs low with the professional management team. That's why ImmuPharma successfully competes with the big pharmaceutical companies on the financial side.